In particular, genomic amplification of MDM2 and promoter-methylation/chromosomal-deletion-mediated inactivation of ARF are present at both diagnosis and relapse in the majority of cases, implying a critical role for the p53-related pathway in neuroblastoma development [36] (Figure 2). This evidence concerns the gene CDKN2A and neuroblastoma.